(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.
The three biggest winners today are Canaan, Ebix, and Redfin.
| Rank | Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|---|
| 1 | Canaan (CAN) | 1.71 | 29.5% | 2023-12-14 12:16:25 |
| 2 | Ebix (EBIX) | 5.48 | 19.16% | 2023-12-14 12:11:59 |
| 3 | Redfin (RDFN) | 9.87 | 17.22% | 2023-12-14 12:17:39 |
| 4 | Crexendo (CXDO) | 3.69 | 16.77% | 2023-12-13 19:42:05 |
| 5 | Fathom Holdings (FTHM) | 2.83 | 16.46% | 2023-12-14 14:23:06 |
| 6 | Eiger BioPharmaceuticals (EIGR) | 0.25 | 14.39% | 2023-12-14 01:42:05 |
| 7 | Bionano Genomics (BNGO) | 1.72 | 14.33% | 2023-12-14 12:16:18 |
| 8 | Enphase Energy (ENPH) | 122.10 | 13.46% | 2023-12-14 12:12:02 |
| 9 | Plug Power (PLUG) | 4.88 | 13.11% | 2023-12-14 12:14:30 |
| 10 | Moderna (MRNA) | 88.72 | 12.88% | 2023-12-14 12:17:15 |
The three biggest losers today are Evelo Biosciences, Whole Earth Brands, and Evofem Biosciences.
| Rank | Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|---|
| 1 | Evelo Biosciences (EVLO) | 0.04 | -49.41% | 2023-12-14 05:10:06 |
| 2 | Whole Earth Brands (FREEW) | 0.07 | -44.31% | 2023-12-14 13:08:06 |
| 3 | Evofem Biosciences (EVFM) | 0.07 | -26.32% | 2023-12-14 05:08:06 |
| 4 | Eloxx Pharmaceuticals (ELOX) | 0.68 | -15% | 2023-12-14 01:43:05 |
| 5 | Enlivex Therapeutics Ltd. (ENLV) | 1.40 | -9.68% | 2023-12-14 01:55:27 |
| 6 | Skillful Craftsman Education Technology Limited (EDTK) | 0.94 | -8.29% | 2023-12-14 01:15:06 |
| 7 | Arthur J. Gallagher & Co. (AJG) | 227.59 | -7.19% | 2023-12-14 12:18:50 |
| 8 | Adobe (ADBE) | 586.62 | -6.03% | 2023-12-14 12:10:20 |
| 9 | Cardinal Health (CAH) | 102.14 | -5.47% | 2023-12-14 12:53:56 |
| 10 | Aon plc (AON) | 319.34 | -4.77% | 2023-12-14 12:52:44 |
Winners today
1. Canaan (CAN) – 29.5%
Canaan Inc. engages in the research, design, and sale of integrated circuit (IC) final mining equipment products by integrating IC products for bitcoin mining and related components in the People's Republic of China. It is also involved in the assembly and distribution of mining equipment and spare parts. The company has operations in the United States, Australia, Kazakhstan, Hong Kong, Canada, Mainland China, Thailand, Sweden, and internationally. Canaan Inc. was founded in 2013 and is based in Singapore.
NASDAQ ended the session with Canaan rising 29.5% to $1.71 on Friday while NASDAQ rose 0.19% to $14,761.56.
Earnings Per Share
As for profitability, Canaan has a trailing twelve months EPS of $-0.47.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -53.23%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Canaan’s EBITDA is 0.53.
Sales Growth
Canaan’s sales growth is negative 38.5% for the current quarter and negative 20.3% for the next.
More news about Canaan.
2. Ebix (EBIX) – 19.16%
Ebix, Inc., together with its subsidiaries, provides on-demand infrastructure software exchanges and e-commerce services to the insurance, financial, travel, cash remittance, and healthcare industries in the United States and internationally. The company develops and deploys insurance and reinsurance exchanges on an on-demand basis using software-as-a-service (SaaS) enterprise solutions in the areas of customer relationship management, front-end and back-end systems, and outsourced administrative and risk compliance solutions. Its EbixCash exchange related products and services include gift cards; travel exchanges services; money transfer services; foreign exchange and outward remittance services; consumer payment services; and on-demand technology to various providers in the areas of lending, wealth and asset management, and travel. The company's insurance exchanges related products and services include SaaS platform and related services; licensing of software; and professional services comprising setup, customization, training, or consulting. Its risk compliance services cover certificates of insurance creation and tracking; consulting services, such as project management, integration, development, and testing; and business process outsourcing services, including domain intensive project management, system consulting services, and claims adjudication/settlement services. The company was formerly known as Delphi Systems, Inc. and changed its name to Ebix, Inc. in December 2003. Ebix, Inc. was founded in 1976 and is headquartered in Johns Creek, Georgia.
NASDAQ ended the session with Ebix jumping 19.16% to $5.48 on Friday, following the last session’s upward trend. NASDAQ rose 0.19% to $14,761.56, after five consecutive sessions in a row of gains, on what was a somewhat positive trend trading session today.
Earnings Per Share
As for profitability, Ebix has a trailing twelve months EPS of $0.16.
PE Ratio
Ebix has a trailing twelve months price to earnings ratio of 34.26. Meaning, the purchaser of the share is investing $34.26 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 0.49%.
Volume
Today’s last reported volume for Ebix is 1187950 which is 46.84% below its average volume of 2235060.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is a negative 69.2% and positive 21.7% for the next.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Ebix’s EBITDA is 0.96.
More news about Ebix.
3. Redfin (RDFN) – 17.22%
Redfin Corporation operates as a residential real estate brokerage company in the United States and Canada. The company operates an online real estate marketplace and provides real estate services, including assisting individuals in the purchase or sell of home. It also provides title and settlement services; and originates and sells mortgages. The company was formerly known as Appliance Computing Inc. and changed its name to Redfin Corporation in May 2006. Redfin Corporation was incorporated in 2002 and is headquartered in Seattle, Washington.
NASDAQ ended the session with Redfin jumping 17.22% to $9.87 on Friday while NASDAQ jumped 0.19% to $14,761.56.
Earnings Per Share
As for profitability, Redfin has a trailing twelve months EPS of $-1.84.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -209.25%.
Volatility
Redfin’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.13%, a positive 1.38%, and a positive 3.83%.
Redfin’s highest amplitude of average volatility was 3.53% (last week), 3.74% (last month), and 3.83% (last quarter).
More news about Redfin.
4. Crexendo (CXDO) – 16.77%
Crexendo, Inc. provides cloud communication platform and services, video collaboration, and managed IT services for businesses in the United States, Canada, and internationally. It operates through two segments, Cloud Telecommunications and Software Solutions. The Cloud Telecommunications segment provides telecommunications services that transmit calls using Internet protocol (IP) or cloud technology, which converts voice signals into digital data packets for transmission over the Internet or cloud; and broadband Internet services. This segment is also involved in the sale and lease of cloud telecommunications equipment. In addition, it offers hardware, software, and unified communication solutions for businesses using IP or cloud technology over high-speed internet connection through various devices and user interfaces, such as desktop phones and/or mobile, and desktop applications under the Crexendo brand name. The Software Solutions segment provides suite of unified communications, video conferencing, collaboration, and contact center solutions. This segment also offers SNAPsolution, a IP-based platform; and SNAPaccel, a software-as-a-service based software, as well as provides subscription maintenance and support, and professional services, including consulting, technical support, resident engineer, design, and installation services. The company was formerly known as iMergent, Inc. and changed its name to Crexendo, Inc. in May 2011. Crexendo, Inc. was incorporated in 1995 and is based in Tempe, Arizona.
NASDAQ ended the session with Crexendo rising 16.77% to $3.69 on Friday, following the last session’s upward trend. NASDAQ rose 0.19% to $14,761.56, after five successive sessions in a row of gains, on what was a somewhat positive trend exchanging session today.
Earnings Per Share
As for profitability, Crexendo has a trailing twelve months EPS of $-1.43.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -60.09%.
Sales Growth
Crexendo’s sales growth is 20.9% for the current quarter and 19.3% for the next.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Mar 29, 2023, the estimated forward annual dividend rate is 0.02 and the estimated forward annual dividend yield is 0.63%.
More news about Crexendo.
5. Fathom Holdings (FTHM) – 16.46%
Fathom Holdings Inc. provides cloud-based real estate brokerage services in the South, Atlantic, Southwest, and Western parts of the United States. The company offers access to various properties for sale or lease through its Website, www.FathomRealty.com to buyers, sellers, landlords, and tenants. It also operates intelliAgent, a real estate technology platform that is designed to provide a suite of brokerage and agent level tools, technology, business processes, business intelligence and reporting, training, customer relationship management, social media marketing, marketing repository, and marketing services, as well as marketplace for add-on services and third-party technology. Fathom Holdings Inc. was founded in 2010 and is headquartered in Cary, North Carolina.
NASDAQ ended the session with Fathom Holdings rising 16.46% to $2.83 on Friday while NASDAQ jumped 0.19% to $14,761.56.
Earnings Per Share
As for profitability, Fathom Holdings has a trailing twelve months EPS of $-1.6.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -40.97%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 15.9%, now sitting on 354.59M for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Fathom Holdings’s EBITDA is 0.17.
Sales Growth
Fathom Holdings’s sales growth is negative 3% for the current quarter and 10% for the next.
More news about Fathom Holdings.
6. Eiger BioPharmaceuticals (EIGR) – 14.39%
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. The company was founded in 2008 and is headquartered in Palo Alto, California.
NASDAQ ended the session with Eiger BioPharmaceuticals rising 14.39% to $0.25 on Friday while NASDAQ jumped 0.19% to $14,761.56.
Earnings Per Share
As for profitability, Eiger BioPharmaceuticals has a trailing twelve months EPS of $-1.95.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -225.93%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 56.1% and 65.4%, respectively.
Sales Growth
Eiger BioPharmaceuticals’s sales growth is 140.4% for the ongoing quarter and 34.8% for the next.
Yearly Top and Bottom Value
Eiger BioPharmaceuticals’s stock is valued at $0.25 at 01:32 EST, way under its 52-week high of $2.98 and way above its 52-week low of $0.20.
Revenue Growth
Year-on-year quarterly revenue growth declined by 20.3%, now sitting on 14.67M for the twelve trailing months.
More news about Eiger BioPharmaceuticals.
7. Bionano Genomics (BNGO) – 14.33%
Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.
NASDAQ ended the session with Bionano Genomics jumping 14.33% to $1.72 on Friday while NASDAQ rose 0.19% to $14,761.56.
Earnings Per Share
As for profitability, Bionano Genomics has a trailing twelve months EPS of $-7.17.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -113.43%.
Sales Growth
Bionano Genomics’s sales growth is 28.3% for the present quarter and 46.5% for the next.
Volume
Today’s last reported volume for Bionano Genomics is 1585070 which is 58.83% above its average volume of 997931.
More news about Bionano Genomics.
8. Enphase Energy (ENPH) – 13.46%
Enphase Energy, Inc., together with its subsidiaries, designs, develops, manufactures, and sells home energy solutions for the solar photovoltaic industry in the United States and internationally. The company offers semiconductor-based microinverter, which converts energy at the individual solar module level, and combines with its proprietary networking and software technologies to provide energy monitoring and control services. It also provides microinverter units and related accessories, an IQ gateway; IQ batteries; the cloud-based Enlighten monitoring service; storage solutions; and electric vehicle charging solutions; and design, proposal, permitting, and lead generation services. The company sells its solutions to solar distributors; and directly to large installers, original equipment manufacturers, strategic partners, and homeowners, as well as through its legacy product upgrade program or online store. Enphase Energy, Inc. was incorporated in 2006 and is headquartered in Fremont, California.
NASDAQ ended the session with Enphase Energy rising 13.46% to $122.10 on Friday while NASDAQ jumped 0.19% to $14,761.56.
Earnings Per Share
As for profitability, Enphase Energy has a trailing twelve months EPS of $3.99.
PE Ratio
Enphase Energy has a trailing twelve months price to earnings ratio of 30.6. Meaning, the purchaser of the share is investing $30.6 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 70.38%.
Sales Growth
Enphase Energy’s sales growth is negative 54.5% for the current quarter and negative 54% for the next.
Volatility
Enphase Energy’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.42%, a positive 0.47%, and a positive 2.94%.
Enphase Energy’s highest amplitude of average volatility was 2.77% (last week), 2.14% (last month), and 2.94% (last quarter).
More news about Enphase Energy.
9. Plug Power (PLUG) – 13.11%
Plug Power Inc. delivers end-to-end clean hydrogen and zero-emissions fuel cell solutions for supply chain and logistics applications, on-road electric vehicles, stationary power market, and others in North America and internationally. It engages in building an end-to-end green hydrogen ecosystem, including liquid green hydrogen production, storage and handling, transportation, and dispensing infrastructure. The company offers GenDrive, a hydrogen-fueled proton exchange membrane (PEM) fuel cell system that provides power to material handling electric vehicles; GenFuel, a liquid hydrogen fueling delivery, generation, storage, and dispensing system; GenCare, an ongoing Internet of Things-based maintenance and on-site service program for GenDrive fuel cell systems, GenSure fuel cell systems, GenFuel hydrogen storage and dispensing products, and ProGen fuel cell engines; and GenSure, a stationary fuel cell solution that offers modular PEM fuel cell power to support the backup and grid-support power requirements of the telecommunications, transportation, and utility sectors. It also provides GenKey, an integrated turn-key solution for transitioning to fuel cell power; ProGen, a fuel cell stack and engine technology used in mobility and stationary fuel cell systems, and as engines in electric delivery vans; Liquefaction systems; and Electrolyzers that are hydrogen generators optimized for clean hydrogen production. The company sells its products through a direct product sales force, original equipment manufacturers, and dealer networks. Plug Power Inc. was founded in 1997 and is headquartered in Latham, New York.
NASDAQ ended the session with Plug Power rising 13.11% to $4.88 on Friday while NASDAQ jumped 0.19% to $14,761.56.
Earnings Per Share
As for profitability, Plug Power has a trailing twelve months EPS of $-1.6.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -24.57%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 5.3%, now sitting on 889.92M for the twelve trailing months.
Volume
Today’s last reported volume for Plug Power is 38376100 which is 18.19% above its average volume of 32467300.
Volatility
Plug Power’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.36%, a negative 0.39%, and a positive 5.54%.
Plug Power’s highest amplitude of average volatility was 2.69% (last week), 4.90% (last month), and 5.54% (last quarter).
More news about Plug Power.
10. Moderna (MRNA) – 12.88%
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a strategic partnership with Caris Life Sciences to advance mRNA-Based oncology therapeutics. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
NASDAQ ended the session with Moderna jumping 12.88% to $88.72 on Friday, following the last session’s upward trend. NASDAQ rose 0.19% to $14,761.56, after five consecutive sessions in a row of gains, on what was a somewhat bullish trend trading session today.
Earnings Per Share
As for profitability, Moderna has a trailing twelve months EPS of $-9.23.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -22.04%.
Sales Growth
Moderna’s sales growth is negative 54.2% for the ongoing quarter and negative 62.8% for the next.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is a negative 141.6% and a negative 1578.9%, respectively.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Moderna’s stock is considered to be overbought (>=80).
Previous days news about Moderna
- : Moderna reorganizes to sharpen focus on vaccine sales, chief commercial officer to leave company. According to MarketWatch on Tuesday, 12 December, "Arpa Garay, previously chief commercial officer, will leave the company in the coming months, Moderna said. "
- Moderna (mrna), Merck start 2nd late-study on cancer therapy. According to Zacks on Tuesday, 12 December, "Over time, Moderna and Merck intend to expand V940 in other oncology indications.", "Merck and Moderna entered a strategic partnership in 2016 to develop and commercialize mRNA-based therapeutics to treat various types of cancer. "
More news about Moderna.
Losers Today
1. Evelo Biosciences (EVLO) – -49.41%
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in clinical development trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also engages in developing EDP1867, an inactivated investigational oral biologic for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
NASDAQ ended the session with Evelo Biosciences dropping 49.41% to $0.04 on Friday while NASDAQ rose 0.19% to $14,761.56.
Earnings Per Share
As for profitability, Evelo Biosciences has a trailing twelve months EPS of $-15.64.
Moving Average
Evelo Biosciences’s worth is way below its 50-day moving average of $1.04 and way below its 200-day moving average of $4.21.
Volume
Today’s last reported volume for Evelo Biosciences is 542580 which is 30.15% below its average volume of 776811.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 82.7% and 80.2%, respectively.
More news about Evelo Biosciences.
2. Whole Earth Brands (FREEW) – -44.31%
Whole Earth Brands, Inc. operates as a food company worldwide. It operates through two segments, Branded CPG and Flavors & Ingredients. The Branded CPG segment focuses on building a branded portfolio serving consumers seeking zero-calorie, low-calorie, organic, non-GMO, no-sugar added, and plant-based, and Fair Trade spaces in zero/low calorie sweeteners, honey, agave, baking mix, and baking chocolate products. It sells products under the Whole Earth, Pure Via, Wholesome, Swerve, Canderel, and Equal brands. This segment offers various sweetener formulations under each brand to address local consumer preferences and price points. The Flavors & Ingredients segment provides functional ingredients with flavoring enhancement, flavor/aftertaste masking, moisturizing, product mouth feel modification, and skin soothing characteristics. This segment also offers licorice-derived products for use in confectionary, food, beverage, cosmetic, pharmaceutical, personal care, and tobacco products applications. The company was incorporated in 2020 and is based in Chicago, Illinois.
NASDAQ ended the session with Whole Earth Brands falling 44.31% to $0.07 on Friday while NASDAQ jumped 0.19% to $14,761.56.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -32.35%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 0.6%, now sitting on 538.65M for the twelve trailing months.
More news about Whole Earth Brands.
3. Evofem Biosciences (EVFM) – -26.32%
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. It has a collaboration agreement with National Community Oncology Dispensing Association, Inc. to educate oncology community about Phexxi. Evofem Biosciences, Inc. is headquartered in San Diego, California.
NASDAQ ended the session with Evofem Biosciences sliding 26.32% to $0.07 on Friday while NASDAQ jumped 0.19% to $14,761.56.
Earnings Per Share
As for profitability, Evofem Biosciences has a trailing twelve months EPS of $38.97.
Volume
Today’s last reported volume for Evofem Biosciences is 2553950 which is 657.08% above its average volume of 337340.
More news about Evofem Biosciences.
4. Eloxx Pharmaceuticals (ELOX) – -15%
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
NASDAQ ended the session with Eloxx Pharmaceuticals sliding 15% to $0.68 on Friday, after two sequential sessions in a row of losses. NASDAQ jumped 0.19% to $14,761.56, after five consecutive sessions in a row of gains, on what was a somewhat up trend trading session today.
Earnings Per Share
As for profitability, Eloxx Pharmaceuticals has a trailing twelve months EPS of $-8.88.
Volume
Today’s last reported volume for Eloxx Pharmaceuticals is 81366 which is 216.51% above its average volume of 25707.
Yearly Top and Bottom Value
Eloxx Pharmaceuticals’s stock is valued at $0.68 at 01:32 EST, under its 52-week low of $0.68.
More news about Eloxx Pharmaceuticals.
5. Enlivex Therapeutics Ltd. (ENLV) – -9.68%
Enlivex Therapeutics Ltd. operates as a clinical stage immunotherapy company. It is developing Allocetra, an off-the-shelf cell therapy designed to reprogram macrophages into homeostatic state. Resetting non-homeostatic macrophages into homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. Diseases, such as solid cancers, sepsis, COVID-19, and others reprogram macrophages out of homeostatic state. Its Allocetra has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents. The company has a research collaboration with Yale Cancer Center for the assessment of Allocetra to enhance the activity of checkpoint inhibitors in solid tumors. Enlivex Therapeutics Ltd. was incorporated in 2005 and is headquartered in Nes Ziona, Israel.
NASDAQ ended the session with Enlivex Therapeutics Ltd. sliding 9.68% to $1.40 on Friday while NASDAQ rose 0.19% to $14,761.56.
Earnings Per Share
As for profitability, Enlivex Therapeutics Ltd. has a trailing twelve months EPS of $-1.47.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -53.23%.
More news about Enlivex Therapeutics Ltd..
6. Skillful Craftsman Education Technology Limited (EDTK) – -8.29%
Skillful Craftsman Education Technology Limited provides vocational online education and technology services to college students and graduates in the People's Republic of China. Its education services cover a range of subjects, including vocational, continuing, and basic education, as well as higher education. It operates three education platforms, including the Lifelong Education Public Service Platform that offers approximately 200 courses; Vocational Training platform, which provides 642 courses covering such as mechanics, electronics, auto repair, and construction subjects; and Virtual Simulation Experimental Training platform that offers 12 experimental programs. The company also offers technology services, including software development and maintenance, hardware installation, and testing and related consulting and training services, as well as cloud services for private companies, academic institutions, and government agencies. Skillful Craftsman Education Technology Limited was founded in 2013 and is headquartered in Wuxi, China.
NASDAQ ended the session with Skillful Craftsman Education Technology Limited dropping 8.29% to $0.94 on Friday, following the last session’s downward trend. NASDAQ rose 0.19% to $14,761.56, after five successive sessions in a row of gains, on what was a somewhat positive trend trading session today.
Earnings Per Share
As for profitability, Skillful Craftsman Education Technology Limited has a trailing twelve months EPS of $-1.4.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -54.15%.
Yearly Top and Bottom Value
Skillful Craftsman Education Technology Limited’s stock is valued at $0.94 at 01:32 EST, way under its 52-week high of $2.09 and way higher than its 52-week low of $0.75.
Moving Average
Skillful Craftsman Education Technology Limited’s value is under its 50-day moving average of $0.94 and way below its 200-day moving average of $1.33.
Volume
Today’s last reported volume for Skillful Craftsman Education Technology Limited is 56721 which is 76.51% above its average volume of 32133.
More news about Skillful Craftsman Education Technology Limited.
7. Arthur J. Gallagher & Co. (AJG) – -7.19%
Arthur J. Gallagher & Co., together with its subsidiaries, provides insurance and reinsurance brokerage, consulting, and third-party property/casualty claims settlement and administration services to businesses and organizations worldwide. It operates in Brokerage and Risk Management segments. The Brokerage segment offers retail and wholesale insurance and reinsurance brokerage services; assists retail brokers and other non-affiliated brokers in the placement of specialized and hard-to-place insurance; and acts as a brokerage wholesaler, managing general agent, and managing general underwriter for distributing specialized insurance coverages to underwriting enterprises. This segment also performs activities, including marketing, underwriting, issuing policies, collecting premiums, appointing and supervising other agents, paying claims, and negotiating reinsurance; and offers services in the areas of insurance and reinsurance placement, risk of loss management, and management of employer sponsored benefit programs. The Risk Management segment provides contract claim settlement and administration services; and claims management, loss control consulting, and insurance property appraisal services. The company offers its services through a network of correspondent brokers and consultants. It serves commercial, industrial, public, religious, and not-for-profit entities, as well as underwriting enterprises. The company was founded in 1927 and is headquartered in Rolling Meadows, Illinois.
NYSE ended the session with Arthur J. Gallagher & Co. dropping 7.19% to $227.59 on Friday, following the last session’s downward trend. NYSE jumped 0.9% to $16,710.06, after five consecutive sessions in a row of gains, on what was a somewhat up trend exchanging session today.
Earnings Per Share
As for profitability, Arthur J. Gallagher & Co. has a trailing twelve months EPS of $5.2.
PE Ratio
Arthur J. Gallagher & Co. has a trailing twelve months price to earnings ratio of 43.77. Meaning, the purchaser of the share is investing $43.77 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.92%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Arthur J. Gallagher & Co.’s EBITDA is 6.17.
Revenue Growth
Year-on-year quarterly revenue growth grew by 19.1%, now sitting on 9.21B for the twelve trailing months.
Volume
Today’s last reported volume for Arthur J. Gallagher & Co. is 1117120 which is 35.71% above its average volume of 823131.
More news about Arthur J. Gallagher & Co..
8. Adobe (ADBE) – -6.03%
Adobe Inc., together with its subsidiaries, operates as a diversified software company worldwide. It operates through three segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products, services, and solutions that enable individuals, teams, and enterprises to create, publish, and promote content; and Document Cloud, a unified cloud-based document services platform. Its flagship product is Creative Cloud, a subscription service that allows members to access its creative products. This segment serves content creators, students, workers, marketers, educators, enthusiasts, communicators, and consumers. The Digital Experience segment provides an integrated platform and set of applications and services that enable brands and businesses to create, manage, execute, measure, monetize, and optimize customer experiences from analytics to commerce. This segment serves marketers, advertisers, agencies, publishers, merchandisers, merchants, web analysts, data scientists, developers, and executives across the C-suite. The Publishing and Advertising segment offers products and services, such as e-learning solutions, technical document publishing, web conferencing, document and forms platform, web application development, and high-end printing, as well as Advertising Cloud offerings. The company offers its products and services directly to enterprise customers through its sales force and local field offices, as well as to end users through app stores and through its website at adobe.com. It also distributes products and services through a network of distributors, value-added resellers, systems integrators, software vendors and developers, retailers, and original equipment manufacturers. The company was formerly known as Adobe Systems Incorporated and changed its name to Adobe Inc. in October 2018. Adobe Inc. was founded in 1982 and is headquartered in San Jose, California.
NASDAQ ended the session with Adobe sliding 6.03% to $586.62 on Friday, following the last session’s downward trend. NASDAQ jumped 0.19% to $14,761.56, after five successive sessions in a row of gains, on what was a somewhat bullish trend trading session today.
Earnings Per Share
As for profitability, Adobe has a trailing twelve months EPS of $11.8.
PE Ratio
Adobe has a trailing twelve months price to earnings ratio of 49.71. Meaning, the purchaser of the share is investing $49.71 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 33.97%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Adobe’s stock is considered to be oversold (<=20).
Yearly Top and Bottom Value
Adobe’s stock is valued at $586.62 at 01:32 EST, under its 52-week high of $628.60 and way above its 52-week low of $318.60.
Previous days news about Adobe
- Adobe had a bang-up 2023, but a tepid 2024 revenue forecast is dinging the stock. According to MarketWatch on Wednesday, 13 December, "For fiscal 2024, Adobe is forecasting $21.33 billion to $21.5 billion in revenue, far short of the consensus $21.73 billion predicted by analysts.", "Compounding matters, Adobe aid it was being probed by the Federal Trade Commission about its subscription practices."
- Adobe systems (adbe) Q4 earnings and revenues top estimates. According to Zacks on Wednesday, 13 December, "While Adobe has outperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?"
- Here's what key metrics tell us about Adobe (adbe) Q4 earnings. According to Zacks on Wednesday, 13 December, "Here is how Adobe performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:"
More news about Adobe.
9. Cardinal Health (CAH) – -5.47%
Cardinal Health, Inc. operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.
NYSE ended the session with Cardinal Health dropping 5.47% to $102.14 on Friday while NYSE rose 0.9% to $16,710.06.
Earnings Per Share
As for profitability, Cardinal Health has a trailing twelve months EPS of $0.61.
PE Ratio
Cardinal Health has a trailing twelve months price to earnings ratio of 167.45. Meaning, the purchaser of the share is investing $167.45 for every dollar of annual earnings.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Dec 28, 2023, the estimated forward annual dividend rate is 2 and the estimated forward annual dividend yield is 1.87%.
More news about Cardinal Health.
10. Aon plc (AON) – -4.77%
Aon plc, a professional services firm, provides advice and solutions to clients focused on risk, retirement, and health worldwide. It offers commercial risk solutions, including retail brokerage, specialty solutions, global risk consulting and captives management, and affinity programs; and health solutions, such as health and benefits brokerages, and health care exchanges. The company also provides treaty and facultative reinsurance, as well as insurance-linked securities, capital raising, strategic advice, restructuring, and mergers and acquisitions services; and corporate finance advisory services. In addition, it offers strategic design consulting services on their retirement programs, actuarial services, and risk management services; advice services on developing and maintaining investment programs across a range of plan types, including defined benefit plans, defined contribution plans, endowments, and foundations for public and private companies, and other institutions; and advice and solutions that help clients in risk, health, and wealth through commercial risk, reinsurance, health, and wealth solutions. Aon plc was founded in 1919 and is headquartered in Dublin, Ireland.
NYSE ended the session with Aon plc falling 4.77% to $319.34 on Friday while NYSE jumped 0.9% to $16,710.06.
Earnings Per Share
As for profitability, Aon plc has a trailing twelve months EPS of $13.18.
PE Ratio
Aon plc has a trailing twelve months price to earnings ratio of 24.23. Meaning, the purchaser of the share is investing $24.23 for every dollar of annual earnings.
Moving Average
Aon plc’s worth is below its 50-day moving average of $324.08 and under its 200-day moving average of $323.60.
Sales Growth
Aon plc’s sales growth is 7.4% for the current quarter and 6.7% for the next.
Volume
Today’s last reported volume for Aon plc is 748375 which is 8.32% below its average volume of 816306.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 4.9% and 13.3%, respectively.
More news about Aon plc.
Stay up to date with our winners and losers daily report
